Abstract: AIM: To investigate the effect of CYP2C19 polymorphism on pharmacokinetic characteristics and 5-hydroxyl metabolic pathway of lansoprazole in Chinese subjects.METHODS: Twelve healthy subjects were typed by using RFLP-PCR method. After intravenous drip 30 mg lansoprazole, the plasma concentrations of lansoprazole in subjects were determined by LC-MS method. The pharmacokinetic parameters of lansoprazole and AUC_LPZ/AUC_{5-OH LPZ} were calculated and compared between different groups.RESULTS: After all the subjects were given 30 mg lansoprazole, it found that the AUC_0-t, AUC_0-∞, CLz, (AUC_LPZ/AUC_5-OH)_0-t and (AUC_LPZ/AUC_5-OH)_0-∞ of the mutant types were equivalent to 2.381, 2.572, 0.428, 3.602 and 4.083-fold as those of the wild types, respectively.CONCLUSION: The CYP2C19 genetic polymorphism, which has significant influence on the pharmacokinetic characteristics of the lansoprazole in Chinese volunteers (P<0.05), has very significant influence on the 5-hydroxyl metabolic pathway of the lansoprazole (P<0.01). The result suggests that CYP2C19 genetic polymorphism is one of the important factors leading to individual concentration differences of the lansoprazole and has a better relevance with the 5-hydroxyl metabolic pathway.

Key words: CYP2C19, Polymorphism, Lansoprazole, Pharmacokinetics